Trump Pressures Drug Companies to Lower Prices

President Donald Trump has reached out to the CEOs of 17 major pharmaceutical companies, including well-known names like Pfizer, Johnson & Johnson, and Eli Lilly.

The purpose of these letters, sent on Thursday, is to push for drug prices that align more closely with the lowest prices available in other developed nations. The administration refers to this approach as “Most Favoured Nation” (MFN) pricing.

The companies targeted by this communication include Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, and several others.

The White House has also published a statement outlining various measures included in the letters:

• Encouraging manufacturers to extend MFN pricing to all Medicaid patients.
• Asking other developed nations to set new drug prices that don’t surpass those available in the U.S.
• Offering a means for drug developers to bypass intermediaries, allowing them to sell medications directly to patients at lower prices.
• Using trade policies to help manufacturers increase their international prices, provided these profits are invested back into reducing U.S. prices for patients and taxpayers.

The letter states if the federal government doesn’t follow these outlined procedures, “we will deploy all our tools in our arsenal to protect American families from continuing abusive drug pricing practices.”

A White House statement also shared striking details about the prescription drug pricing landscape in the U.S., explaining the urgency behind these actions.

It noted that while only about 5% of the U.S. population is using prescription drugs, a staggering 75% of global profits in the pharmaceutical industry come from U.S. taxpayers.

Drug prices in the U.S. are significantly higher than those in other wealthy countries. Even after accounting for manufacturer discounts, Americans frequently pay two to four times more, sometimes exceeding 300%, for the same drugs that OECD members pay much less for.

In one of his letters, Trump stated, “This unacceptable burden on hardworking American families will end in my administration.”

During a press conference, Press Secretary Karoline Leavitt read a letter sent to Eli Lilly’s CEO. The letter acknowledged that drug companies have previously made similar commitments but failed to follow through while seeking significant financial support from policy changes.

“The only thing I’m accepting from drug makers going forward is my commitment to providing American families with immediate relief from the inflated drug prices,” Leavitt said.

Moreover, Trump referred to an executive order signed on May 12, which demands “most favored nation prescription drug pricing for American patients.” He argued that Americans shouldn’t have to subsidize cheaper drugs available in other countries while they face higher prices at home.

This order has ignited discussions with drug manufacturers about providing MFN pricing to American consumers.

Leavitt wrapped up the press conference by mentioning that the remaining letters from the president would be shared with reporters afterward.